| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Dihydropteroate synthase (DHPS) in the bacterial folate synthesis pathway. Succinylsulfathiazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, an enzyme involved in the synthesis of folic acid. The compound acts as a competitive inhibitor of p-aminobenzoic acid (PABA), a substrate for DHPS. By inhibiting folate synthesis, the compound prevents the production of nucleotides and nucleic acids, leading to bacterial growth inhibition.
|
|---|---|
| ln Vitro |
Succinylsulfathiazole is a sulfonamide antibiotic with antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria. As a prodrug, it is metabolized in the gastrointestinal tract to release the active antibacterial agent sulfathiazole. The compound exhibits bacteriostatic activity, inhibiting bacterial growth rather than directly killing bacteria. Its antibacterial spectrum includes Escherichia coli, Shigella, Salmonella, and other enteric pathogens. The compound is poorly absorbed from the GI tract, which limits its systemic effects and focuses its activity on intestinal infections.
|
| ln Vivo |
In vivo, Succinylsulfathiazole is poorly absorbed from the gastrointestinal tract, resulting in high concentrations in the intestinal lumen. It is metabolized in the gut to release sulfathiazole, which exerts antibacterial activity against intestinal pathogens. The compound has been used clinically for the treatment of ulcerative colitis, enteritis, and other intestinal infections. It is also used for preoperative bowel sterilization to reduce the risk of infection during intestinal surgery.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing is performed using broth dilution or agar dilution methods according to CLSI or EUCAST guidelines. Bacterial strains (e.g., E. coli, Shigella, Salmonella) are cultured in Mueller-Hinton broth or agar. Varying concentrations of Succinylsulfathiazole (0.125-256 μg/mL) are added to the medium. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth after 18-24 hours of incubation at 37°C. For enzyme assays, dihydropteroate synthase inhibition is measured using cell-free bacterial extracts or purified enzyme, with PABA as substrate. Inhibition of enzyme activity is determined by measuring product formation.
|
| Cell Assay |
No specific cell-based assay protocols are documented for Succinylsulfathiazole. For antibacterial activity testing, bacterial cells (not mammalian cells) are used in susceptibility assays. Bacteria are cultured in appropriate media and treated with varying concentrations of the compound. Bacterial growth is measured by optical density at 600 nm or by colony counting. The compound's bacteriostatic effect is determined by comparing growth in treated vs. untreated cultures. For mechanistic studies, bacterial folate levels or nucleotide synthesis may be measured.
|
| Animal Protocol |
In animal models, Succinylsulfathiazole is administered orally to rodents in models of intestinal infection or for bowel sterilization. For infection models, animals are infected with pathogenic bacteria (e.g., Shigella, Salmonella) and treated with the compound orally. Efficacy is assessed by bacterial counts in stool or intestinal tissue, survival rates, and clinical signs of infection. For bowel sterilization studies, animals are treated with the compound and fecal bacterial counts are monitored. The compound is poorly absorbed, resulting in high intestinal concentrations and minimal systemic exposure.
|
| ADME/Pharmacokinetics |
Succinylsulfathiazole is a sulfonamide antibiotic with poor oral bioavailability due to limited gastrointestinal absorption. This property is advantageous for intestinal infections as it results in high drug concentrations in the intestinal lumen while minimizing systemic exposure and side effects. The compound is metabolized in the gastrointestinal tract to release the active antibacterial agent sulfathiazole. It is eliminated primarily in the feces. The compound should be stored as powder under appropriate conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for Succinylsulfathiazole. As a sulfonamide antibiotic, it may cause side effects including gastrointestinal disturbances, allergic reactions, and, rarely, hematological effects (agranulocytosis, hemolytic anemia) or hypersensitivity reactions (Stevens-Johnson syndrome). The compound is contraindicated in patients with sulfonamide allergy, severe renal impairment, or porphyria. Standard safety precautions should be observed when handling the compound. The compound is intended for research use only.
|
| Additional Infomation |
N-Succinylsulfathiazole belongs to the 1,3-thiazole class of compounds, and its function is similar to that of sulfathiazole.
Succinylsulfathiazole is a sulfonamide antibiotic used for the treatment of intestinal infections including ulcerative colitis, enteritis, and for preoperative bowel sterilization. It is a prodrug that is metabolized in the GI tract to release the active antibacterial agent sulfathiazole. The compound is poorly absorbed, resulting in high intestinal concentrations. It acts by inhibiting bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth. The compound is also known as sulfasuxidine. It is intended for research use only. |
| Molecular Formula |
C13H13N3O5S2
|
|---|---|
| Molecular Weight |
355.3894
|
| Exact Mass |
355.029
|
| CAS # |
116-43-8
|
| PubChem CID |
5315
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Melting Point |
187 - 193ºC
|
| Index of Refraction |
1.679
|
| LogP |
0.68
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
526
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])C(C([H])([H])C([H])([H])C(=O)O[H])=O)(N([H])C1=NC([H])=C([H])S1)(=O)=O
|
| InChi Key |
SKVLYVHULOWXTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H13N3O5S2/c17-11(5-6-12(18)19)15-9-1-3-10(4-2-9)23(20,21)16-13-14-7-8-22-13/h1-4,7-8H,5-6H2,(H,14,16)(H,15,17)(H,18,19)
|
| Chemical Name |
4-oxo-4-[4-(1,3-thiazol-2-ylsulfamoyl)anilino]butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~281.38 mM)
H2O : ~1 mg/mL (~2.81 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8138 mL | 14.0691 mL | 28.1381 mL | |
| 5 mM | 0.5628 mL | 2.8138 mL | 5.6276 mL | |
| 10 mM | 0.2814 mL | 1.4069 mL | 2.8138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
